|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Supplement 3. Data Extraction Template | | | | | | | | |
|  | van der Lugt, 2010 | Heald et al, 2012 | Ramel, 2013 | Scheurer, 2016 | Tottman, 2017 | Tottman, 2018 | Zamir, 2019 | Gonzalez Villamizar, 2020 |
| Location |  |  |  |  |  |  |  |  |
| Study design |  |  |  |  |  |  |  |  |
| Population |  |  |  |  |  |  |  |  |
| Intervention/Exposure |  |  |  |  |  |  |  |  |
| Comparator |  |  |  |  |  |  |  |  |
| Sample size |  |  |  |  |  |  |  |  |
| Definition (hyperglycemia) |  |  |  |  |  |  |  |  |
| Incidence (hyperglycemia) |  |  |  |  |  |  |  |  |
| Measurement of blood glucose (i.e. plasma or whole blood) |  |  |  |  |  |  |  |  |
| Treatment of hyperglycemia (details of NICU protocol, duration/dose of insulin, #hypoglycemia episodes) |  |  |  |  |  |  |  |  |
| Hypoglycemia (duration/#), reported (yes/no), included as a confounder (yes/no/na) |  |  |  |  |  |  |  |  |
| Age at follow-up for outcome measures |  |  |  |  |  |  |  |  |
| Growth outcomes measured (weight, OFC, height) |  |  |  |  |  |  |  |  |
| Metabolic outcomes measured (Blood pressures, glucose metabolism, fasting glucose, insulin, body composition, etc.) |  |  |  |  |  |  |  |  |
| Neurodevelopment outcomes measured (exam, learning, attention, executive function, autism, motor, cognitive, etc.) |  |  |  |  |  |  |  |  |
| Sex-specific outcomes reported (are males/females different between groups, are outcomes analyzed separately between sexes) |  |  |  |  |  |  |  |  |
| Follow-up rates |  |  |  |  |  |  |  |  |
| Adjustments for potential confounding |  |  |  |  |  |  |  |  |